{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T06:49:57Z","timestamp":1791614997249,"version":"4.3.4"},"reference-count":49,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T00:00:00Z","timestamp":1781568000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/501100001807","name":"S\u00e3o Paulo Research Foundation","doi-asserted-by":"publisher","award":["2022\/15002-8"],"award-info":[{"award-number":["2022\/15002-8"]}],"id":[{"id":"10.13039\/501100001807","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003593","name":"CNPq","doi-asserted-by":"publisher","award":["386246\/2024-6"],"award-info":[{"award-number":["386246\/2024-6"]}],"id":[{"id":"10.13039\/501100003593","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001807","name":"FAPESP","doi-asserted-by":"publisher","award":["2023\/17546-8"],"award-info":[{"award-number":["2023\/17546-8"]}],"id":[{"id":"10.13039\/501100001807","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001807","name":"FAPESP","doi-asserted-by":"publisher","award":["2023\/07482-2"],"award-info":[{"award-number":["2023\/07482-2"]}],"id":[{"id":"10.13039\/501100001807","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,10,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Sodium\u2013glucose co-transporter-2 inhibitors (SGLT2i) are a crucial therapy for chronic kidney disease (CKD), yet concerns persist regarding their impact on bone metabolism. This systematic review evaluates the skeletal safety and metabolic effects of SGLT2i in patients with CKD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A systematic review of randomized controlled trials (RCTs) and observational cohort studies was conducted. Data on study design, population characteristics, baseline kidney function, bone-related comorbidities, and outcomes (osteoporosis, fractures, falls, amputations, and bone mineral markers) were summarized. Risk of bias was evaluated according to the included category.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The analysis revealed that while one RCT and a cohort study reported a significantly increased risk of bone fracture and amputation, this finding was not replicated in other subsequent cohort studies and other RCTs, which generally showed non-significant differences. Of note, the reporting of bone-related outcomes was inconsistent throughout the literature, and a substantial proportion of the evidence derives from studies primarily designed for patients with type 2 diabetes, largely involving early-stage CKD subgroups. One study suggests that SGLT2i may favorably modulate markers of CKD-mineral bone disease (MBD), reporting reduced risk of hyperphosphatemia, hypocalcemia, high parathyroid hormone, and low vitamin D levels. The reviewed literature primarily included data on empagliflozin, canagliflozin, dapagliflozin, and ertugliflozin.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Mostly, SGLT2i demonstrated a possible reassuring skeletal safety profile in CKD. Initial safety concerns regarding fractures have not been consistently supported, although evidence in moderate-to-advanced CKD remains limited. Long-term, prospectively defined skeletal outcomes are needed to confirm these findings and clarify class effects.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/joneph\/aajag035","type":"journal-article","created":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T12:28:04Z","timestamp":1770726484000},"page":"1116-1128","source":"Crossref","is-referenced-by-count":2,"title":["Effects of gliflozins on bone health of patients with chronic kidney disease: a systematic review"],"prefix":"10.1093","volume":"39","author":[{"given":"Mariana","family":"Cassani de Oliveira","sequence":"first","affiliation":[{"name":"Laboratory for Evaluation of Mineral and Bone Disorder in Nephrology (LEMON), School of Medical Sciences, State University of Campinas (Unicamp) , Campinas, S\u00e3o Paulo ,","place":["Brazil"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorena","family":"Rufino","sequence":"additional","affiliation":[{"name":"Laboratory for Evaluation of Mineral and Bone Disorder in Nephrology (LEMON), School of Medical Sciences, State University of Campinas (Unicamp) , Campinas, S\u00e3o Paulo ,","place":["Brazil"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Laura","family":"Mendes Louren\u00e7o","sequence":"additional","affiliation":[{"name":"Laboratory for Evaluation of Mineral and Bone Disorder in Nephrology (LEMON), School of Medical Sciences, State University of Campinas (Unicamp) , Campinas, S\u00e3o Paulo ,","place":["Brazil"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric Arag\u00e3o","family":"Corr\u00eaa","sequence":"additional","affiliation":[{"name":"Laboratory for Evaluation of Mineral and Bone Disorder in Nephrology (LEMON), School of Medical Sciences, State University of Campinas (Unicamp) , Campinas, S\u00e3o Paulo ,","place":["Brazil"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6879-9344","authenticated-orcid":false,"given":"Fabrice","family":"Mac-Way","sequence":"additional","affiliation":[{"name":"CHU de Qu\u00e9bec Research Center, L\u2019H\u00f4tel-Dieu-de-Qu\u00e9bec Hospital, Endocrinology and Nephrology Axis, Quebec City, Quebec ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauter Eston","family":"Pelepenko","sequence":"additional","affiliation":[{"name":"Laboratory for Evaluation of Mineral and Bone Disorder in Nephrology (LEMON), School of Medical Sciences, State University of Campinas (Unicamp) , Campinas, S\u00e3o Paulo ,","place":["Brazil"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niels Olsen Saraiva","family":"C\u00e2mara","sequence":"additional","affiliation":[{"name":"Department of Immunology, Institute of Biomedical Science - ICB of the University of S\u00e3o Paulo\u2014USP , S\u00e3o Paulo ,","place":["Brazil"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodrigo Bueno","family":"de Oliveira","sequence":"additional","affiliation":[{"name":"Laboratory for Evaluation of Mineral and Bone Disorder in Nephrology (LEMON), School of Medical Sciences, State University of Campinas (Unicamp) , Campinas, S\u00e3o Paulo ,","place":["Brazil"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,6,16]]},"reference":[{"key":"2026101002222854600_aajag035-B1","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1016\/j.ekir.2022.04.094","article-title":"Prescribing SGLT2 inhibitors in patients with CKD: expanding indications and practical considerations","volume":"7","author":"Yau","year":"2022","journal-title":"Kidney Int reports"},{"key":"2026101002222854600_aajag035-B2","doi-asserted-by":"publisher","first-page":"10848","DOI":"10.1021\/acs.jmedchem.2c00867","article-title":"Sodium-glucose cotransporter inhibitors as antidiabetic drugs: current development and future perspectives","volume":"65","author":"Maccari","year":"2022","journal-title":"J Med Chem"},{"key":"2026101002222854600_aajag035-B3","doi-asserted-by":"publisher","first-page":"F889","DOI":"10.1152\/ajprenal.00267.2015","article-title":"Renal sodium-glucose cotransporter inhibition in the management of type 2 diabetes mellitus","volume":"309","author":"Abdul-Ghani","year":"2015","journal-title":"Am J Physiol Renal Physiol"},{"key":"2026101002222854600_aajag035-B4","doi-asserted-by":"publisher","first-page":"279","DOI":"10.2215\/CJN.09380822","article-title":"Kidney-protective effects of SGLT2 inhibitors","volume":"18","author":"Palmer","year":"2023","journal-title":"Clin J Am Soc Nephrol"},{"key":"2026101002222854600_aajag035-B5","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1038\/s41574-020-0392-2","article-title":"Sodium\u2013glucose cotransporter type 2 inhibitors for the treatment of type 2 diabetes mellitus","volume":"16","author":"Scheen","year":"2020","journal-title":"Nat Rev Endocrinol"},{"key":"2026101002222854600_aajag035-B6","doi-asserted-by":"publisher","first-page":"1788","DOI":"10.1016\/S0140-6736(22)02074-8","article-title":"Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials","volume":"400","author":"Nuffield Department of Population Health Renal Studies Group, SGLT2 inhibitor Meta-Analysis Cardio-Renal Trialists\u2019 Consortium","year":"2022","journal-title":"Lancet"},{"key":"2026101002222854600_aajag035-B7","doi-asserted-by":"publisher","first-page":"100851","DOI":"10.1016\/j.xkme.2024.100851","article-title":"SGLT2 inhibitor use in chronic kidney disease: supporting cardiovascular, kidney, and metabolic health","volume":"6","author":"Madero","year":"2024","journal-title":"Kidney Med"},{"key":"2026101002222854600_aajag035-B8","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and cardiovascular outcomes in type 2 diabetes","volume":"380","author":"Wiviott","year":"2019","journal-title":"N Engl J Med"},{"key":"2026101002222854600_aajag035-B9","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N Engl J Med"},{"key":"2026101002222854600_aajag035-B10","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N Engl J Med"},{"key":"2026101002222854600_aajag035-B11","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1007\/s12325-021-01994-2","article-title":"Chronic kidney disease and SGLT2 inhibitors: a review of the evolving treatment landscape","volume":"39","author":"Mende","year":"2022","journal-title":"Adv Ther"},{"key":"2026101002222854600_aajag035-B12","doi-asserted-by":"publisher","first-page":"iii73","DOI":"10.1093\/eurheartjsupp\/suaf019","article-title":"Preserving renal function: gliflozins, GLP1 agonists, and antialdosterones","volume":"27","author":"Cice","year":"2025","journal-title":"Eur Heart J Suppl"},{"key":"2026101002222854600_aajag035-B13","doi-asserted-by":"publisher","first-page":"379","DOI":"10.3390\/jcm12010379","article-title":"Gliflozins: From Antidiabetic Drugs to Cornerstone in Heart Failure Therapy\u2014A Boost to Their Utilization and Multidisciplinary Approach in the Management of Heart Failure","volume":"12","author":"Pistelli","year":"2023","journal-title":"J Clin Med"},{"key":"2026101002222854600_aajag035-B14","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1038\/ki.2013.356","article-title":"Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control","volume":"85","author":"Kohan","year":"2014","journal-title":"Kidney Int"},{"key":"2026101002222854600_aajag035-B15","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1210\/jc.2015-3167","article-title":"Effects of canagliflozin on fracture risk in patients with type 2 diabetes Mellitus","volume":"101","author":"Watts","year":"2016","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"2026101002222854600_aajag035-B16","first-page":"139","article-title":"SGLT2 inhibitors: new reports","volume":"57","year":"2015","journal-title":"Med Lett Drugs Ther"},{"key":"2026101002222854600_aajag035-B17","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1186\/s12902-024-01575-8","article-title":"Effects of sodium-glucose cotransporter 2 inhibitors on bone metabolism in patients with type 2 diabetes mellitus: a systematic review and meta-analysis","volume":"24","author":"Wang","year":"2024","journal-title":"BMC Endocr Disord"},{"key":"2026101002222854600_aajag035-B18","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1038\/s41581-018-0028-0","article-title":"Adverse effects of SGLT2 inhibitors on bone health","volume":"14","author":"Blau","year":"2018","journal-title":"Nat Rev Nephrol"},{"key":"2026101002222854600_aajag035-B19","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/S2213-8587(14)70227-X","article-title":"Possible adverse effects of SGLT2 inhibitors on bone","volume":"3","author":"Taylor","year":"2015","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2026101002222854600_aajag035-B20","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1080\/00325481.2017.1256747","article-title":"Bone effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in patients with type 2 diabetes mellitus","volume":"129","author":"Blevins","year":"2017","journal-title":"Postgrad Med"},{"key":"2026101002222854600_aajag035-B21","author":"US Food and Drug Administration"},{"key":"2026101002222854600_aajag035-B22","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med"},{"key":"2026101002222854600_aajag035-B23","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N Engl J Med"},{"key":"2026101002222854600_aajag035-B24","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N Engl J Med"},{"key":"2026101002222854600_aajag035-B25","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1210\/jc.2015-1860","article-title":"Evaluation of bone mineral density and bone biomarkers in patients with type 2 diabetes treated with canagliflozin","volume":"101","author":"Bilezikian","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"key":"2026101002222854600_aajag035-B26","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1111\/dom.12189","article-title":"Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metformin","volume":"16","author":"Bolinder","year":"2014","journal-title":"Diabetes Obes Metab"},{"key":"2026101002222854600_aajag035-B27","first-page":"1","article-title":"Dapagliflozin cardiovascular effects on end-stage kidney disease (DARE-ESKD-2) trial: rationale and design","volume":"12","author":"Barreto","year":"2024","journal-title":"Expert Opin Drug Saf"},{"key":"2026101002222854600_aajag035-B28","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.2215\/CJN.0000000000000196","article-title":"Pharmacokinetic properties of dapagliflozin in hemodialysis and peritoneal dialysis patients","volume":"18","author":"Barreto","year":"2023","journal-title":"Clin J Am Soc Nephrol"},{"key":"2026101002222854600_aajag035-B29","doi-asserted-by":"publisher","first-page":"e1000100","DOI":"10.1371\/journal.pmed.1000100","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration","volume":"6","author":"Liberati","year":"2009","journal-title":"PLoS Med"},{"key":"2026101002222854600_aajag035-B30","doi-asserted-by":"publisher","first-page":"i4919","DOI":"10.1136\/bmj.i4919","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions","volume":"355","author":"Sterne","year":"2016","journal-title":"BMJ"},{"key":"2026101002222854600_aajag035-B31","doi-asserted-by":"publisher","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"Rob 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"2026101002222854600_aajag035-B32","doi-asserted-by":"publisher","first-page":"b2535","DOI":"10.1136\/bmj.b2535","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"339","author":"Moher","year":"2009","journal-title":"BMJ"},{"key":"2026101002222854600_aajag035-B33","doi-asserted-by":"publisher","first-page":"835","DOI":"10.2215\/CJN.16171221","article-title":"Fracture risk of sodium-glucose cotransporter-2 inhibitors in chronic kidney disease","volume":"17","author":"Cowan","year":"2022","journal-title":"Clin J Am Soc Nephrol"},{"key":"2026101002222854600_aajag035-B34","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.amjcard.2024.04.011","article-title":"Kidney and cardiovascular effectiveness of empagliflozin compared with dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes","volume":"221","author":"Edmonston","year":"2024","journal-title":"Am J Cardiol"},{"key":"2026101002222854600_aajag035-B35","doi-asserted-by":"publisher","first-page":"2532","DOI":"10.1111\/dom.13413","article-title":"Efficacy and safety of dapagliflozin in patients with type 2 diabetes and moderate renal impairment (chronic kidney disease stage 3A): the DERIVE study","volume":"20","author":"Fioretto","year":"2018","journal-title":"Diabetes Obes Metab"},{"key":"2026101002222854600_aajag035-B36","doi-asserted-by":"publisher","first-page":"592","DOI":"10.2215\/CJN.0000000000000115","article-title":"Safety of sodium-glucose cotransporter-2 inhibitors in patients with CKD and type 2 diabetes: population-based US cohort study","volume":"18","author":"Fu","year":"2023","journal-title":"Clin J Am Soc Nephrol"},{"key":"2026101002222854600_aajag035-B37","doi-asserted-by":"publisher","first-page":"240","DOI":"10.2337\/cd19-0087","article-title":"Patient and provider characteristics associated with sodium\u2013glucose cotransporter 2 inhibitor prescription in patients with diabetes and proteinuric chronic kidney disease","volume":"38","author":"McCoy","year":"2020","journal-title":"Clin Diabetes"},{"key":"2026101002222854600_aajag035-B38","doi-asserted-by":"publisher","first-page":"1870","DOI":"10.1007\/s11606-024-08793-9","article-title":"Empagliflozin and risk of incident gout: analysis from the EMPagliflozin comparative effectiveness and SafEty (EMPRISE) cohort study","volume":"39","author":"Tesfaye","year":"2024","journal-title":"J\u00a0Gen Intern Med"},{"key":"2026101002222854600_aajag035-B39","doi-asserted-by":"publisher","first-page":"E178","DOI":"10.1503\/cmaj.240922","article-title":"Sodium-glucose cotransporter 2 (SGLT2) inhibitors and risk of chronic kidney disease-mineral and bone disorders in patients with type 2 diabetes mellitus and stage 1-3 chronic kidney disease","volume":"197","author":"Tsai","year":"2025","journal-title":"C Can Med Assoc J = J l\u2019Association medicale Can"},{"key":"2026101002222854600_aajag035-B40","doi-asserted-by":"publisher","first-page":"3538","DOI":"10.1111\/dom.15249","article-title":"Efficacy and safety of the sodium-glucose co-transporter-2 inhibitor empagliflozin in elderly Japanese adults (\u226565 years) with type 2 diabetes: a randomized, double-blind, placebo-controlled, 52-week clinical trial (EMPA-ELDERLY)","volume":"25","author":"Yabe","year":"2023","journal-title":"Diabetes Obes Metab."},{"key":"2026101002222854600_aajag035-B41","doi-asserted-by":"publisher","first-page":"66","DOI":"10.2215\/CJN.04530418","article-title":"Effects of dapagliflozin on circulating markers of phosphate homeostasis","volume":"14","author":"de Jong","year":"2019","journal-title":"Clin J Am Soc Nephrol"},{"key":"2026101002222854600_aajag035-B42","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.2337\/db15-1356","article-title":"Shift to fatty substrate utilization in response to sodium\u2013glucose cotransporter 2 inhibition in subjects without diabetes and patients with type 2 diabetes","volume":"65","author":"Ferrannini","year":"2016","journal-title":"Diabetes"},{"key":"2026101002222854600_aajag035-B43","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.kint.2017.12.027","article-title":"Renoprotective effects of sodium-glucose cotransporter-2 inhibitors","volume":"94","author":"Heerspink","year":"2018","journal-title":"Kidney Int"},{"key":"2026101002222854600_aajag035-B44","doi-asserted-by":"publisher","first-page":"68","DOI":"10.20945\/2359-3997000000440","article-title":"Dose-ranging effects of SGLT2 inhibitors in patients with type 2 diabetes: a systematic review and meta-analysis","volume":"66","author":"Pinto","year":"2022","journal-title":"Arch Endocrinol Metab"},{"key":"2026101002222854600_aajag035-B45","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/j.diabres.2018.10.019","article-title":"Sodium-glucose cotransporter 2 inhibitors and fracture risk in patients with type 2 diabetes mellitus: a systematic literature review and Bayesian network meta-analysis of randomized controlled trials","volume":"146","author":"Azharuddin","year":"2018","journal-title":"Diabetes Res Clin Pract"},{"key":"2026101002222854600_aajag035-B46","doi-asserted-by":"publisher","first-page":"918350","DOI":"10.3389\/fendo.2022.918350","article-title":"The extraglycemic effect of SGLT-2is on mineral and bone metabolism and bone fracture","volume":"13","author":"Dong","year":"2022","journal-title":"Front Endocrinol"},{"key":"2026101002222854600_aajag035-B47","doi-asserted-by":"publisher","first-page":"e022577","DOI":"10.1136\/bmjopen-2018-022577","article-title":"Comparative safety of the sodium glucose co-transporter 2 (SGLT2) inhibitors: a systematic review and meta-analysis","volume":"9","author":"Donnan","year":"2019","journal-title":"BMJ Open"},{"key":"2026101002222854600_aajag035-B48","doi-asserted-by":"publisher","first-page":"3170","DOI":"10.1002\/dmrr.3170","article-title":"Effects of SGLT2 inhibitors on fractures and bone mineral density in type 2 diabetes: an updated meta-analysis","volume":"35","author":"Li","year":"2019","journal-title":"Diabetes Metab Res Rev"},{"key":"2026101002222854600_aajag035-B49","doi-asserted-by":"publisher","first-page":"2826","DOI":"10.1007\/s12325-024-02879-w","article-title":"Safety of empagliflozin: an individual participant-level data meta-analysis from four large trials","volume":"41","author":"Wanner","year":"2024","journal-title":"Adv Ther"}],"container-title":["Journal of Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/joneph\/article-pdf\/39\/6\/1116\/68535581\/aajag035.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/joneph\/article-pdf\/39\/6\/1116\/68535581\/aajag035.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T06:22:34Z","timestamp":1791613354000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/joneph\/article\/39\/6\/1116\/8709044"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,16]]},"references-count":49,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2026,6,16]]},"published-print":{"date-parts":[[2026,10,10]]}},"URL":"https:\/\/doi.org\/10.1093\/joneph\/aajag035","relation":{},"ISSN":["1121-8428","1724-6059"],"issn-type":[{"value":"1121-8428","type":"print"},{"value":"1724-6059","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,7]]},"published":{"date-parts":[[2026,6,16]]}}}